April 1, 2014 Eagle Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office has granted Patent No. 8,685,460 for the treatment of …
NDA for Eagle Pharmaceuticals’ Orphan Drug Ryanodex® for the Treatment of Malignant Hyperthermia Accepted by FDA, Priority Review Granted
March 19, 2014 Eagle Pharmaceuticals, Inc. announced today that the United States Food and Drug Administration has accepted the company’s New Drug Application for Ryanodex® …